RE: rise20 Nov 2020 11:00
Mowser, I can see a likeness in that it's a bandwagon that many companies have thrown themselves on and it's obviously attracted a lump of hot retail money. We're getting in to the thick of it now though, this winter is likely to be peak covid as through next year vaccines and testing solutions emerge - in particular winners and losers. The markets will have more longevity than first thought, but for many companies it's been an opportunity they couldn't ignore. On the GDR presentation yesterday the CEO gave an answer to a question about comms by saying he's trying to build a company for long term sustainable success and they've deliberately chosen not to be the type of company that puts out PR fluff. He didn't come out and say that he doesn't give a sh.t about retail investors and their hot money and impatience, but it's pretty obvious that's the view. Whether we like it or not, as retail investors, we've shoved a bunch of cash in to a sector that was previously ignored and so you can't really blame the CEOs in taking a placing opportunity as they're more than aware the retail cash will disappear as fast as it arrived. The question is which of the companies that have cashed in can make the most of the immediate opportunity and then further capitalise on that for the longer term. In my view that's where awacta comes in to its own. They've targeted the most challenging but rewarding testing market and the oncology business that will benefit has enormous potential. In doing so, I'm sure they'll have converted some of the crypto style punters in to long term holders.
Sign In
Follow the stocks
